Note to Affiliate: This document is based on the November 2023 Irish SmPC, the August 2020 J Tube IFU, the March 2019 NJ Tube IFU, the August 2020 PEG IFU, the 2019 CADD Duodopa Patient Information Guide, and the February 2019 CADD Duodopa Pump Operator's Manual.
Duodopa (levodopa/carbidopa intestinal gel) is for the treatment of advanced levodopa-responsive Parkinson’s disease with severe motor fluctuations and hyperkinesia or dyskinesia when available combinations of Parkinson medicinal products have not given satisfactory results1
People in this piece are models, not actual patients.
People in this piece are models, not actual patients.
Duodopa (levodopa/carbidopa intestinal gel) is for the treatment of advanced levodopa-responsive Parkinson’s disease with severe motor fluctuations and hyperkinesia or dyskinesia when available combinations of Parkinson medicinal products have not given satisfactory results1
People in this piece are models, not actual patients.
Because ON TIME is their time
RESOURCES
Helpful resources and answers to some frequently asked questions about Duodopa
DOWNLOADS
Duodopa Snapshot Brochure
Frequently Asked Questions (FAQ)
General
[Placeholder for Affiliates to add local Important Treatment Considerations or remove]
[Placeholder for Affiliates to add local Important Treatment Considerations or remove]
[Placeholder for Affiliates to add local Important Treatment Considerations or remove]
[Placeholder for Affiliates to add local Important Treatment Considerations or remove]
[Placeholder for Affiliates to add local Important Treatment Considerations or remove]
[Placeholder for Affiliates to add local Important Treatment Considerations or remove]
Duodopa Initiation
Local guidelines should be followed. A temporary NJ tube should be considered to determine if the patient responds favorably to this method of treatment before a permanent PEG-J is placed. In cases where the physician considers this assessment is not necessary, the NJ test phase may be waived and treatment initiated directly with placement of the PEG-J.1 The morning dose and continuous maintenance dose should be based on the patient’s previous morning intake of levodopa and daily intake of levodopa, respectively.1
Local guidelines should be followed. A temporary NJ tube should be considered to determine if the patient responds favorably to this method of treatment before a permanent PEG-J is placed. In cases where the physician considers this assessment is not necessary, the NJ test phase may be waived and treatment initiated directly with placement of the PEG-J.1 The morning dose and continuous maintenance dose should be based on the patient’s previous morning intake of levodopa and daily intake of levodopa, respectively.1
Local guidelines should be followed. A temporary NJ tube should be considered to determine if the patient responds favorably to this method of treatment before a permanent PEG-J is placed. In cases where the physician considers this assessment is not necessary, the NJ test phase may be waived and treatment initiated directly with placement of the PEG-J.1 The morning dose and continuous maintenance dose should be based on the patient’s previous morning intake of levodopa and daily intake of levodopa, respectively.1
Local guidelines should be followed. A temporary NJ tube should be considered to determine if the patient responds favorably to this method of treatment before a permanent PEG-J is placed. In cases where the physician considers this assessment is not necessary, the NJ test phase may be waived and treatment initiated directly with placement of the PEG-J.1 The morning dose and continuous maintenance dose should be based on the patient’s previous morning intake of levodopa and daily intake of levodopa, respectively.1
Local guidelines should be followed. A temporary NJ tube should be considered to determine if the patient responds favorably to this method of treatment before a permanent PEG-J is placed. In cases where the physician considers this assessment is not necessary, the NJ test phase may be waived and treatment initiated directly with placement of the PEG-J.1 The morning dose and continuous maintenance dose should be based on the patient’s previous morning intake of levodopa and daily intake of levodopa, respectively.1
After Care
[Note to affiliate. Please check latest local versions or documents are used in any links in the FAQ section]
The PEG-J tube should be mobilized by pushing 3-4 cm into the stoma and moving back and forth every time the dressing is changed. When doing so the tube should not be turned or rotated under any circumstances to prevent the formation of loops and dislocation of the J tube.2
The PEG-J tube should be mobilized by pushing 3-4 cm into the stoma and moving back and forth every time the dressing is changed. When doing so the tube should not be turned or rotated under any circumstances to prevent the formation of loops and dislocation of the J tube.2
Pump Guidance & Operation
The dose will be programmed, and can only be modified, by the doctor in charge. Before changing the programmed dose, the pump should be set to lock level 0 (LL0).6 Full instructions on dose adjustment are given in the Operator’s Manual.5
The dose will be programmed, and can only be modified, by the doctor in charge. Before changing the programmed dose, the pump should be set to lock level 0 (LL0).6 Full instructions on dose adjustment are given in the Operator’s Manual.5
The dose will be programmed, and can only be modified, by the doctor in charge. Before changing the programmed dose, the pump should be set to lock level 0 (LL0).6 Full instructions on dose adjustment are given in the Operator’s Manual.5
The dose will be programmed, and can only be modified, by the doctor in charge. Before changing the programmed dose, the pump should be set to lock level 0 (LL0).6 Full instructions on dose adjustment are given in the Operator’s Manual.5
The dose will be programmed, and can only be modified, by the doctor in charge. Before changing the programmed dose, the pump should be set to lock level 0 (LL0).6 Full instructions on dose adjustment are given in the Operator’s Manual.5
The dose will be programmed, and can only be modified, by the doctor in charge. Before changing the programmed dose, the pump should be set to lock level 0 (LL0).6 Full instructions on dose adjustment are given in the Operator’s Manual.5
The dose will be programmed, and can only be modified, by the doctor in charge. Before changing the programmed dose, the pump should be set to lock level 0 (LL0).6 Full instructions on dose adjustment are given in the Operator’s Manual.5
The dose will be programmed, and can only be modified, by the doctor in charge. Before changing the programmed dose, the pump should be set to lock level 0 (LL0).6 Full instructions on dose adjustment are given in the Operator’s Manual.5
The dose will be programmed, and can only be modified, by the doctor in charge. Before changing the programmed dose, the pump should be set to lock level 0 (LL0).6 Full instructions on dose adjustment are given in the Operator’s Manual.5
The dose will be programmed, and can only be modified, by the doctor in charge. Before changing the programmed dose, the pump should be set to lock level 0 (LL0).6 Full instructions on dose adjustment are given in the Operator’s Manual.5
The dose will be programmed, and can only be modified, by the doctor in charge. Before changing the programmed dose, the pump should be set to lock level 0 (LL0).6 Full instructions on dose adjustment are given in the Operator’s Manual.5
The dose will be programmed, and can only be modified, by the doctor in charge. Before changing the programmed dose, the pump should be set to lock level 0 (LL0).6 Full instructions on dose adjustment are given in the Operator’s Manual.5
The dose will be programmed, and can only be modified, by the doctor in charge. Before changing the programmed dose, the pump should be set to lock level 0 (LL0).6 Full instructions on dose adjustment are given in the Operator’s Manual.5
Complications, Warnings & Alarms
Please report all adverse events and adverse drug effects directly to our drug safety department.
[Placeholder for Affiliates to add local information]
There may be a kink in the tubing or a clamp may be closed. Unkink the tubing or open the clamp and the pump will resume delivery.
Press ‘STOP/START or ‘NEXT‘ to stop the pump and silence the alarm for 2 minutes. After the cause of the high pressure has been removed, start the pump to continue delivery. If the alarm continues, the clinician responsible for the care should be contacted.
[Placeholder for Affiliates to add local information]
There may be a kink in the tubing or a clamp may be closed. Unkink the tubing or open the clamp and the pump will resume delivery.
Press ‘STOP/START or ‘NEXT‘ to stop the pump and silence the alarm for 2 minutes. After the cause of the high pressure has been removed, start the pump to continue delivery. If the alarm continues, the clinician responsible for the care should be contacted.
[Placeholder for Affiliates to add local information]
There may be a kink in the tubing or a clamp may be closed. Unkink the tubing or open the clamp and the pump will resume delivery.
Press ‘STOP/START or ‘NEXT‘ to stop the pump and silence the alarm for 2 minutes. After the cause of the high pressure has been removed, start the pump to continue delivery. If the alarm continues, the clinician responsible for the care should be contacted.
[Placeholder for Affiliates to add local information]
Everyday Life, Travelling & Carrier Systems
The Duodopa pump is only splash-proof, it must be removed before showering or bathing.7
The Duodopa pump is only splash-proof, it must be removed before showering or bathing.7
The Duodopa pump is only splash-proof, it must be removed before showering or bathing.7
The Duodopa pump is only splash-proof, it must be removed before showering or bathing.7
The Duodopa pump is only splash-proof, it must be removed before showering or bathing.7
The Duodopa pump is only splash-proof, it must be removed before showering or bathing.7
The Duodopa pump is only splash-proof, it must be removed before showering or bathing.7
EVENTS
Details of forthcoming congresses at which AbbVie will be present
EVENTS 2024
10th European Academy of Neurology Congress
29 June - 2 July, 2024
International Congress of Parkinson's Disease and Movement Disorders
27 September - 1 October, 2024
I want to receive more information via a product specialist
References
- Duodopa (levodopa/carbidopa intestinal gel) SmPC; [insert current data]
- AbbVie PEG information for users.
- AbbVie J information for users.
- AbbVie NJ information for users.
- Legacy Duodopa Operator’s Manual. CADD Legacy Duodopa Pump Model 1400.
- AbbVie. Duodopa PEG/J Aftercare Guideline. Risk Management Plan version 7.2.
- Legacy Duodopa Patient Information. CADD Legacy Duodopa Pump Model 1400.
- Duodopa patient information leaflet.